Canalia (Dexlansoprazole)
Description
Canalia (Dexlansoprazole) delayed release capsule has been characterized as a gastric Proton Pump Inhibitor (PPI) that blocks the final step of gastric acid production. It is the R-enantiomer of Lansoprazole (a racemic mixture of the R- and S-enantiomers).
Presentation
Composition:
Canalia-30 Capsule: Each capsule contains Dexlansoprazole INN 30 mg as
enteric coated pellets.
Canalia-60 Capsule: Each capsule contains Dexlansoprazole INN 60 mg as
enteric coated pellets.
Indications
Canalia Capsule is indicated for
a) Treating heartburn associated with symptomatic Non-Erosive Gastroesophageal Reflux Disease (GERD)
b) Healing of all grades of Erosive Esophagitis (EE)
c) Maintaining healing of EE and relief of heartburn
Dosage & Administration
Canalia (Dexlansoprazole) capsule is administered orally before or after food.
The recommended doses of Dexlansoprazole for adults are as follows:
| Indication | Recommended Dose | Dose Frequency |
| Symptomatic Non-Erosive GERD | 30 mg | Once daily for 4 weeks |
| Healing of EE | 60 mg | Once daily for up to 8 weeks |
| Maintenance of Healed EE and relief of heartburn | 30 mg | Once daily for up to six months |
Contrainidications
Dexlansoprazole is contraindicated in patients with known hypersensitivity to any component of the formulation.
Warning & Precautions
Most commonly reported adverse reactions are diarrhea, abdominal pain, nausea, upper respiratory tract infection, vomiting etc.
